Oncternal Therapeutics Inc (ONCT)

[dinogreeves]

So I read, this could run very, very hard to the appropriate valuation, they just need to layoff direct or public offering. To reach only Velosbios 25% valuation, this stock will hit $35.00. Show us the data on the 11th, then a massive a run to the teens is very highly likely.

Sat down and re-read the 10k and basically VelosBios was founded by the same people as ONCT. ONCT creates an LLC called Velos Biopharm Holdings in Delaware and then licenses the ADC product to the holding company. Meanwhile, they have Dave Johnson "found" VelosBio becoming its CEO. Subsequently, the holding company (comprised of Breitmeyer, Garner, Hale, Cooper, LaRue, and Glenn) becomes the only shareholder of VelosBio. Conveniently, they now have their holding company sublicense the ADC to VelosBio corporation. This allows Breitmeyer and his buddies to have their fingers in both ONCT and Velosbio. Supposedly, when the holding company was formed, ONCT shareholders received an in-kind distribution at that time in 2017 -- not sure what it was, but probably very small given that they state that the chance of success was low. Don't know what the status of the holding company is anymore -- maybe they sold out to early investors or maybe they still hold shares in Velosbio?

[dinogreeves]

This is either running for an offering, or running based on Merck buying out their competitor for 2.75 billion dollars. It could run to the teens.

Oncternal Therapeutics, Inc.
We are a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for cancers with critical unmet medical need. Our development efforts are focused on promising, yet untapped, biological pathways implicated in cancer generation or progression. Our pipeline includes cirmtuzumab, an investigational monoclonal antibody that is designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1, or ROR1, a growth factor receptor that is widely expressed on many tumors and that activates pathways leading to increased tumor proliferation, invasiveness and drug resistance. Cirmtuzumab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib (Imbruvica®) (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma, or CIRLL) for the treatment of patients with B-cell lymphoid malignancies, including mantle cell lymphoma, or MCL, and chronic lymphocytic leukemia, or CLL, and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. We are also developing TK216, an investigational small molecule that is designed to inhibit the ETS, or E26 Transformation Specific, family of oncoproteins. ETS alterations have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. TK216 is being evaluated in a Phase 1 clinical trial as a single agent and in combination with vincristine in patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer. In addition, we are developing a chimeric antigen receptor T cell, or CAR-T, therapy candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
Cirmtuzumab is an investigational, humanized, potentially first-in-class, anti-ROR1 monoclonal antibody that is designed to bind to a specific functionally important epitope of ROR1. ROR1, which is a protein expressed on many tumors, is a potentially attractive target for cancer therapy because it is an onco-embryonic antigen, which is a protein typically expressed only during embryogenesis that may confer a survival and fitness advantage when reactivated and expressed by tumor cells. ROR1 overexpression in various tumor types, including MCL, CLL and breast cancer, has been associated with more aggressive disease, resistance to therapy and shorter progression-free and overall survival. In preclinical models, inhibition of ROR1 has shown anti-tumor activity, and we believe may have additive or synergistic effects when combined with either targeted therapy or chemotherapy. Preclinical data indicated that when cirmtuzumab bound to ROR1, it blocked growth factor Wnt5a signaling, inhibited tumor cell proliferation, migration and survival, and induced differentiation of CLL tumor cells. Cirmtuzumab was developed in the laboratory of one of our scientific advisors, Professor Thomas Kipps, M.D., Ph.D., Professor of Medicine and Evelyn and Edwin Tasch Chair in Cancer Research at the University of California San Diego, or UC San Diego, with support from the California Institute for Regenerative Medicine, or CIRM. We have an exclusive license to cirmtuzumab for therapeutic uses from UC San Diego.
On June 30, 2020, we announced an updated clinical strategy for cirmtuzumab that prioritizes development in MCL, based on encouraging interim clinical results from the CIRLL Phase 1/2 clinical trial that were presented at the American Society of Clinical Oncology 2020 Virtual Annual Meeting in May 2020. As a result, we are amending the CIRLL study to increase the number of patients with relapsed/refractory MCL to be enrolled in the



S-1
Table of Contents

Phase 2 expansion cohort to at least 20 patients and to allow the enrollment of patients with a broader range of prior Bruton’s tyrosine kinase inhibitor treatments. In addition, we intend to limit the total enrollment of CLL patients in the CIRLL study to up to 30 patients, in order to focus resources on the MCL portion of the study. We currently expect to meet with the U.S. Food and Drug Administration, or FDA, in the next few weeks to discuss the recent interim results from the CIRLL study and to seek guidance on a potential accelerated approval pathway for cirmtuzumab plus ibrutinib in patients with relapsed/refractory MCL. There can be no assurance that the FDA will agree with our planned clinical trial design for relapsed/refractory MCL or our plans to seek an accelerated approval pathway. We expect to announce new data from the CIRLL trial in patients with MCL and CLL at a scientific conference in the fourth quarter of 2020. Cirmtuzumab is also being evaluated in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel in patients with HER2 negative breast cancer. We expect to announce data from this Phase 1b clinical trial at a scientific conference in the first half of 2021. Additionally, we plan to further explore clinical combination strategies for cirmtuzumab for patients with hematologic malignancies. For example, we are supporting an investigator-sponsored Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL in collaboration with UC San Diego. We continue to evaluate cirmtuzumab in additional ROR1-expressing tumors and expect to complete preclinical studies that could support an investigational new drug application, or IND, in the second half of 2020.
On June 30, 2020, we also announced that the FDA has granted orphan drug designations of cirmtuzumab for the treatment of MCL and for the treatment of CLL/small lymphocytic lymphoma.
TK216 is an investigational, potentially first-in-class, targeted small molecule that is designed to specifically inhibit the biological activity of the ETS family of oncoproteins. Tumorigenic gene fusions involving ETS factors are frequently found in tumors such as Ewing sarcoma and prostate cancer, and ETS factors are often overexpressed in other tumors, such as acute myeloid leukemia, or AML, and diffuse large B cell lymphoma, or DLBCL. Researchers in the laboratory of Professor Jeffrey Toretsky, M.D., at Georgetown Lombardi Comprehensive Cancer Center, identified the precursor to TK216 using a novel chemical screening assay they developed based on a deep understanding of the underlying biological mechanism of ETS factors. Following this early work, TK216, which is designed to be a specific inhibitor of ETS factors, was created by us through the rational design and screening of novel small molecule inhibitors of a critical protein-protein interaction. In preclinical models, TK216 inhibited the interaction between ETS family members and RNA helicase A, or RHA, and by doing so, shut down excessive cell proliferation. We own intellectual property related to TK216 and have an exclusive license to product candidates targeting ETS oncoproteins for therapeutic, diagnostic or research tool purposes from Georgetown University.
We are evaluating TK216 as a single agent and in combination with vincristine in an open-label, multicenter Phase 1 clinical trial in patients with relapsed/refractory Ewing sarcoma. The dose-finding portion of the study was completed in 2019, and we are enrolling patients in an expansion cohort to evaluate the clinical response of treatment with TK216 in combination with vincristine using the recommended Phase 2 dosing regimen. We anticipate announcing clinical data for 12 to 16 patients dosed in this expansion cohort in the fourth quarter of 2020. Ewing sarcoma is a rare pediatric cancer that has historically been very challenging to treat effectively, particularly for recurrent and metastatic disease. ETS fusion proteins have been shown to be present in over 90% of Ewing sarcoma cases. TK216 has received an Orphan Drug Designation and Fast Track Designation from the FDA for the treatment of Ewing sarcoma. We continue to evaluate TK216 in additional ETS-driven tumors and expect to complete preclinical studies that could support an IND in the second half of 2020.
We are also developing a ROR1-targeted CAR-T therapy utilizing the binding domain of cirmtuzumab as a single-chain fragment variable, or scFv fragment, as a potential treatment for patients with aggressive hematological malignancies or solid tumors. Because cirmtuzumab has been shown to bind to multiple cancers but not to normal adult tissues in preclinical studies, we believe that a cirmtuzumab-based CAR-T may be selective in distinguishing cancer from normal tissues. Our ROR1-targeted CAR-T therapy candidate is in preclinical development in collaboration with UC San Diego, supported by funding from CIRM, and with



S-2
Table of Contents

Shanghai Pharmaceuticals Holding Co., Ltd., or SPH, in China. We expect the first-in-human dosing of our ROR1-targeted CAR-T therapy in China in 2021.
Pipeline
The following figure summarizes our current programs:

[dinogreeves]

Some say, sympathy play of AP*VO, I say nothing to do with AP*VO, nothing. This is going to run on totally different reasons.

[dinogreeves]

88.2M cap @ 4$
221M Cap @ 10$
441M Cqp @ 20$
882M cap @ 40$
2.746B cap @160$

15-20$, just saying at least for next week


Expect massive manipulation on this which started already on Thursday.

[dinogreeves]

ONCT on fire all next week. Only if you knew what the reason is. Just watch

[kex0414]

With my years of experience, the perfect formula for DD of OTC below:
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.

[mdstocks]

ONCT GM Luna, I won't lie about it , it has been tough to sit with a stock, stay positive and maintain a high level of hope that by some miracle I will recoup my loss and break even.....and I admit, it has challenged the fabric of my soul. Considering my value was down 91% with the r/s then the offering. Add in hard lined manipulation, and most would have sold to recoup what they could, and a rare breed, hating to admit failure, have stuck with this stock knowing that the company has no revenue stream, only grants and even those are not very hefty......I think the company is betting on a hope and a prayer that they will get lucky with positive result and cause a huge interested party will offer them bails of Benjamin's for their research and drawn conclusions. So far over the last two day it has gone up over 450%.

Will it hold? Your guess is as good if not better than mine, but my fingers are crossed, all else seems to allude my success, research, DD and scouring the available historical info, so I will just sit, watch, wait and will recoup, at a minimum my investment.....all things considered is a good thing.

GLTY and here's to looking on for the brighter side of $10.00 or more per share.

Momentum was very aggressive starting Thursday.

Down side, weekend (bad gugu).

Up side, really low float that has easily turned over several times.

Low priced shares are hard to come by but with all runs, they are only as fruitful as the creativeness of the manipulators...institutional holders that play from 1am to 4am (my guess) then add in the MM, Brokers, alert groups and any of the other factions that resemble a "one armed bandit" rather than a retail buyer. A buyer that carries an attack hue for all others to join together and steal the retail traders hard earned money.

I better stop for now...geeeezzz I don't mean to misled anyone with some negativity that leaks out, I love the game!!!

[kex0414]

Yep! I only own a few hundred shares, but up is better than down. I took ONCT off my "Favorites" list and put a +25 cent alert in place. I just sat and watched ETrade Pro, after-hour trading on my 55" monitor (TV screen). It was my Friday Night Movie. (I don't have a social life).
Hope the Chartists don't start screaming, "Gotta fill the gap".

[mdstocks]

ONCT Luna,funny you should ask....yep sure do....I'm a true believer that patience will prevail and am very hopeful that I will do handsomely in the end....How's bout you?

[kex0414]

Nice move after hours

[kex0414]

Still own ONTC !!!!!!!!!!!!!!!!!

[ClayTrader]

* * $ONCT Video Chart 11-05-2020 * *

Link to Video - click here to watch the technical chart video

[kex0414]

8K out. Good news. Up pre-market

[knoxlube]

I've been trading this stock since just before the GTXI/ONCT RM, and still holding a small 185 share core position since that time. Otherwise, I've been buying and selling ONCT as the situation warrants for whatever gains possible. Despite recent positive news, it appears that EOY tax loss selling is ruling current pps trend? I will continue to add at these levels or lower in anticipation of much better days ahead in early 2020.

All IMO. GLTA & ONCT!

[kex0414]

8K out

[kex0414]

Interesting article...

cost effective testing

[knoxlube]

Thanks for posting that link, md. Good info to know, IMO. Limited release, huh? Wonder why? I've not been able to find it elsewhere although I'll check further later. I also added 50 shares @ $5.35 based on that article. And to lower my PPS avg a bit more. I was hoping to get them under $5 but decided to go ahead and get a few before the price goes up. :p Will see how ONCT responds as word gets out and in the days ahead.

GLTA & ONCT!

[mdstocks]

ONCT

Heads up: AH and Limited release news link could get real interesting:

http://investor.oncternal.com/node/15571/pdf

JMO

[knoxlube]

Well, I can't argue with that. Overpaid executives seems to be the case in many of these "Penny Stock" gambles. So you got your CVR's as well, which are "worthless" at this point in time and likely will remain so? I think the stock is subject to being heavily shorted at will. Notice that the PPS is down over 6% at the moment and may be under $5 before the end of the week or until buying kicks in from some of the bigger players, swingers and/or flippers (which is my usual strategy once I get stuck, and until I can safely exit). But I don't invest large sums in any stock unless I believe that it's an almost sure thing, which I don't feel ONCT is. It's volatility is fairly high comparatively speaking. Oddly enough, the R/M did nothing for GTXI SH's as our PPS has been in the dumpster ever since. The PPS did go over $8 once but I didn't sell all the shares I could and should have at that time. ;p

Anyway, bottom line, I agree with you. Just not a lot that can be done about it now. If ONCT comes across any extra cash, it would also be nice if they would use it to repurchase some of their shares or better yet, let's see some of the highly paid execs spend some of their paychecks to purchase a few shares to go along with all those they've been given. Maybe things will change soon? Time will tell, always does.

All IMO. GL 2 US and ONCT!

[mdstocks]

ONCT I am a post merger and R/S shareholder. The company is not concerned whether shareholder/investors make any money....they don't even have a revenue stream. All their funds are donated or grants. After reading about the new hires that were given 150k share of stock and somewhere in the neighborhood of $400k salary. I suggested to them if they found some more tens of thousand or or maybe hundred of thousands of fund just laying around they should declare a very hefty dividend for shareholders/investors to show their appreciation. I also feel they could and would benefit from familiarizing themselves with their " duties". Doctors too arrogant to think for one moment that they owed anyone anything...until that happens...I'll hope for a group that pulls a P&D, make my money and move on.

GLTU

[knoxlube]

You are correct! Very quiet on this board, but I don't hear any crickets? ;p I don't think there are a large number of retail SH's that post here as this hasn't been much of a P & D stock since the R/M. So far, no PR or ER of consequence. I've made a little money trading ONCT, but still have some $1+ shares when it was trading under GTXI before the R/M that are now in the $7.5-$9 range. I'd need approx $8 pps to break even but not worried with less than 500 shares after the R/M and selling the "gains". Just trade ONCT while you wait and see if anything happens down the road? It's all I'm doing. Or you can "Short" it. I'll start adding if and when the pps goes below $4.90. Do you or have you ever owned GTXI shares? TIA and appreciate your post!

ALL IMO. GLTY & ONCT!

[mdstocks]

ONCT Wow, it is so quiet here .... nothing but crickets. Probably because the company has no source of revenue other than grants and donations. My guess is that they have no plan for increasing the shareholder/investor value. Quite a sad state of affairs, I guess the bottom line here is this: if your not employed by the company you may never see any kind of return on your investment. But if your employed by the company they pay you quite handsomely. 150k shares of stock and an annual salery of $400k if I have a correct recollection. I hate tom say it but here it ism anyways.....what a POS.....GTXI was a POS and ONCT is even a bigger POS....F&^$!!!!

[robertus]

Nice to see higher high finally

[robertus]

Onct press release yesterday I found it with Seeking alpha

Oncternal Reports Second Quarter 2019 Financial Results and Provides Business Update $ONCT https://seekingalpha.com/pr/17598869

[Money $hot]

ONCT

[robertus]

It would need some publicity then more buyers would be expected. Until that big boys are accumulating. Anyway it is a new stock now, only ex Gtxi owners are keeping ONCT on their radars.

[knoxlube]

Well, the pps has traveled down a bit since your last post. I added a few just above $5 on 7/15 and added a few more at $4.15 and quite a few more at $3.45 on 8/2. ONCT is looking better since then, although I think the MM's and Shorts are still working on it?

In case anyone on here is interested, ONCT released this today which may have had something to do with it's recovery although vol was a paltry 6.8K. May be some slow readers!? ;p

http://investor.oncternal.com/news-releases/news-release-details/oncternal-therapeutics-announces-opening-randomized-phase-2

Could we see a larger gain tomorrow? Who knows? I'm looking forward to reading ONCT's first "combined" ER, expected shortly, although not expecting any actual "Earnings"?

All IMO. GLTA & ONCT!

[robertus]

Nice action today +6,5%
Any news good news could send it much higher

[robertus]

Me too I keep a small position and I will buy some more soon.
Not sure about shorts. Maybe retail owners selling.

[knoxlube]

Yes, indeed! About as quiet as this board! ;p So far, ONCT is best for trading, just as GTXI was immediately following the failure of their latest drug trial, and the weeks leading up to the R/M and R/S. I sold off a lot of my shares on the run up to $8 shortly after the R/M and should have sold them all! But I didn't and instead added shares back at $5.20, and plan to add more this week if I can get them at $4.20 or less. It would appear that ONCT is being heavily shorted and is oversold at this stage, and is due for a recovery, with or without news!

All IMO! GLTA & ONCT!

[MOCKBA]

Total silence from the company....strange

[robertus]

What we can see is very low volume since merger. It could explode when good news comes out.

[paps3]

ok thanks

[MOCKBA]

Why you wanna sell now? And call your broker...

[paps3]

Why GTXI stocks options are still under restriction ? not letting me sell. Anyone please.

[Obelax]

Righte direction....

[mdstocks]

ONCT

I cant remember the last time I saw a Reverse Merger go south so quickly without a breather. Over 33% down in two day. The companies silence is unforgivable. They have botched this reverse merger at every turn. These companies that take short cut to the NASDAQ don't have a clue.

I also know I sound like a basher however, I am invested heavily and this should have gone soooooo differently.

GLTA

I've written Oncternal twice and not a peep from the company.

"Houston we have a problem"

[MOCKBA]

Just look at all the Form 4s posted today, crazy amounts of pre split shares purchased!! Over 4 mill of them!
I say go with the paper trail....someone is throwing millions of $$ in here, must be a reason?

[Obelax]

Baaack to 1,20$ total fail invest here

[Obelax]

Next bad Day... All RS to run negativ

[MOCKBA]

This is the ONCT board, it will change name, takes time, relax Rome wasnt build in one day

[Obelax]

No ONCT Board and Symbol of Ihub

[mdstocks]

ONCT

Considering Fridays close was 1.20 or 8.40 at todays rate .... I don't see that as a stop loss error...all things considered this stock should be much much higher. The trading is so unorthodox .... but hay what do I know....Lets hope for a better day and close continued in AH.

GLTA

[Obelax]

Ihub Symbol not found :-/

[kex0414]

A request has been sent to Admin to change Board to ONCT.

That low ball sell could have been a stop-loss error or market order. Can't believe it was intentional. Pre and Post Market trading can be fun, but dangerous if not careful.

[mdstocks]

ONCT the new GTXI

Hopefully the weak, uncalculating hands will be wiped out and real traders who know the value of what they have will have the shares.

GO ONCT

[MOCKBA]

Yeap, saw that in pre market

[mdstocks]

ONCT the new GTXI

Trading is very strange.....its as if traders are unaware of what they have and what is not available....if they did I don't think the pps would be this low....disappointing. There was a trade at $4.34 and if you do the math that equates to .62 the 52 wk low before the R/S was .74 ..... go figure

[MOCKBA]

Nothing issued at Schwab yet....and i dont like this price action so far

[mdstocks]

GTXI

Now ONCT

I think they should issue calculators with the new shares. Geeeeez